Pitching company River BioMedics in the spotlight
November 10, 2022
River BioMedics was founded on a novel, human iPSC-derived, 3D cardiac strip platform which represents human heart function, in an in vitro setting. The technology allows direct effects on human cardiac tissue of modification of drug target activity, to be measured at the very beginning of the drug discovery process. River exploits this in-house technology to validate novel cardiac drug discovery targets, identified from human genome wide association studies (GWAS) in heart failure.